Okay. Thank you, Mr. MacLeod.
My next question is to Dr. Lynd. During her appearance before the committee, an official from the PMPRB highlighted several challenges facing the organization, including controlling the high cost of drugs, especially drugs such as biologics, oncology drugs, and orphan drugs. In her testimony, the PMPRB official identified the need for the PMPRB's legal and regulatory framework to adapt to these changing circumstances and efforts to remain relevant and effective in protecting consumers from excessive pricing.
In your view, how does the PMPRB need to evolve in order to better control the high prices, especially for drugs such as biologics, oncology drugs, and orphan drugs?